Access to precision cancer medicine relies on correctly isolating cancer cells from a biopsy, a difficult task with existing methods. SynderBio has developed a patented cell separation technology, unlocking the potential of genomic sequencing for cancer diagnostics, single-cell sequencing, and broader life science applications. Genomic markers can define precision treatments in cancer, but difficulties in processing biopsy samples limit routine use.